Guggenheim Securities has reaffirmed Celldex Therapeutics as its top pick in the biotechnology sector, citing what the firm views as substantial commercial potential for the company’s lead asset, barzolvolimab, in the chronic urticaria market as late-stage clinical data approaches.
Analysts at the brokerage reiterated a Buy rating on Celldex shares and maintained a $100 price target, arguing that current market expectations do not fully reflect barzolvolimab’s potential addressable revenue.
Guggenheim provided a peak-sales framework for the therapy, estimating roughly $3 billion in global peak sales under base assumptions. The firm also outlined an upside scenario - $3 billion to $5 billion - contingent on Phase III outcomes matching the strong efficacy observed in Phase II studies and on the drug’s use widening to additional indications.
The firm described the chronic spontaneous urticaria market as poised for rapid growth as newer, more effective therapies gain traction. In its market sizing, Guggenheim estimated that approximately 580,000 moderate-to-severe patients in the United States remain inadequately controlled by antihistamines, and that current biologic penetration in the population is about 20 percent, indicating a substantial runway for increased uptake.
Guggenheim highlighted barzolvolimab’s reported attributes - namely efficacy, durability, and activity in difficult-to-treat patients - as supporting the case for premium pricing should the therapy reach market.
The brokerage also flagged several upcoming clinical milestones that it views as potential catalysts for the stock: topline Phase III EMBARQ-CSU1 and EMBARQ-CSU2 data expected in September or October, Phase II results in atopic dermatitis due later this year, and additional clinical updates for CDX-622.
Investors and market participants will likely watch the approaching readouts closely given their potential to confirm Phase II performance and to influence commercial projections and pricing assumptions.